United States · FDA National Drug Code directory
UBRELVY
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 0023-6498_a4b2fc64-0045-4595-8194-98b7f2734d5e
- Product NDC
- 0023-6498
- Form
- TABLET
- Composition / generic term
- ubrogepant
- Labeler
- Allergan, Inc.
- Marketing category
- NDA
- Marketing start / end (source format)
- 20191223
- Source listing expiry
- 20271231
Source-listed ingredients
- UBROGEPANT — 50 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 1 PACKET in 1 BOX (0023-6498-01) / 1 TABLET in 1 PACKET · 0023-6498-01
- 4 PACKET in 1 BOX (0023-6498-04) / 1 TABLET in 1 PACKET · 0023-6498-04
- 10 PACKET in 1 BOX (0023-6498-10) / 1 TABLET in 1 PACKET (0023-6498-02) · 0023-6498-10
- 16 PACKET in 1 BOX (0023-6498-16) / 1 TABLET in 1 PACKET (0023-6498-02) · 0023-6498-16
- 30 PACKET in 1 BOX (0023-6498-30) / 1 TABLET in 1 PACKET (0023-6498-02) · 0023-6498-30
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →